Sign in to view content

A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years

Aaron Nagiel, MD, PhD

Video
Published 2024

Related

Wet AMD 2 Symposium
Annual Meeting Talks
2020
Episode 155: Argus II Quality of Life Improvements and More with Dr. Jacque Duncan
Jayanth Sridhar, MD
Member Podcasts
2018
3-Year Update for the Phase 3 Voretigene Neparvovecrzyl Study in Biallelic RPE65 Mutation–Associated Inherited Retinal Disease
Stephen R. Russell, MD
Updates from the Field
2018

Category: Hereditary Retinal Disease & Genetics

See more